Skip to content
EmergingResearch compoundReference only

Nebracetam

Experimental Japanese-developed nootropic known only from rat and laboratory studies; not tested in humans.

NootropicRacetamCholinergicRacetamAcetylcholineAcetylcholineDopamineSerotonin

Pharmacology

ClassRacetam · Acetylcholine
Primary targetM1 muscarinic acetylcholine receptor agonist
Targets3 receptor targets
Half-lifeN/A (no human data)
OnsetN/A (no human pharmacokinetic data)
EvidenceReference only
Affected systemsAcetylcholineDopamineSerotonin

Contents

DETAILED OVERVIEW

What is Nebracetam?

Nebracetam (development code WEB 1881 FU) is an experimental compound from the racetam family, studied in Japanese research. It is not a marketed medicine anywhere and is not recognized as a dietary supplement. It is not approved in the United States, and in Australia it is classed as prescription-only.

It directly switches on one of the brain's acetylcholine receptors (acetylcholine is a messenger involved in learning and memory). In rats it increased the production and release of acetylcholine and gave modest protection to nerve cells from damage after disturbed blood supply to the brain. A laboratory experiment on human cells suggests it may act the same way in humans, but no clinical trial has been done in people, so neither its effect nor its safety in humans is known. Based on its mechanism, it could in theory cause nausea, diarrhea and a slow heartbeat; it may need to be avoided in asthma, heart rhythm problems and ulcers. There is no safety data for pregnancy and breastfeeding.

Mechanism

M1 muscarinic agonist + cholinergic

Evidence

Preclinical (rat, in vitro)

Half-life

N/A (no human data)

Legal status

Investigational (not marketed)

Receptor profile

  • M1 muscarinic ACh receptorStrong
  • High-affinity choline uptake / ACh releaseModerate
  • Neuroprotection (cerebral ischemia)Moderate

Safety

Side effects, stop signs, contraindications

Side effects · 5

  • No human safety data exist; the following are theoretical risks inferred from the cholinergic (muscarinic agonist) mechanism, not observed effects
  • Nausea, diarrhea or abdominal cramping, typical of muscarinic overstimulation
  • Increased salivation, sweating or lacrimation (peripheral cholinergic effects)
  • Headache, as with many other racetams
  • Theoretical cardiovascular risk: bradycardia or a drop in blood pressure can occur with muscarinic agonism

Contraindications · 6

  • Pregnancy and breastfeeding: no safety data, should be avoided
  • Not studied for human use: with no clinical data it is not recommended for human consumption and should be treated only as a research reference
  • Bradycardia or cardiac conduction disorder: muscarinic agonism may further slow heart rate
  • Asthma or COPD: muscarinic activation may trigger bronchoconstriction
  • Peptic ulcer or gastrointestinal disease: increased gastric acid and motility are possible
  • Concurrent anticholinergic medications: they may mutually blunt each other's effects

Related Nootropics

Same therapeutic category

Studies

Related research and clinical findings

FAQ

FAQ

Nebracetam is a Japanese-developed racetam compound with cholinergic effects, it directly activates one of the brain's acetylcholine receptors, so in theory it could support memory and learning. In rat models it boosted acetylcholine production and release, and showed mild nerve-protective effects in certain brain circulation problems. This too is a purely research-stage substance, backed only by animal and lab (in vitro) data, it has not been studied in humans.

Telegram

Have a question about Nebracetam?

Reach out to us on Telegram for a personalized stack. We'll be happy to help.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

Structure & chemistry

TypeNootropic
FormulaC12H16N2O
UpdatedOctober 13, 2026
MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: October 13, 2026

The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.